RT Journal Article
SR Electronic
T1 Protection from Omicron infection in residents of nursing and retirement homes in Ontario, Canada
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.28.22277016
DO 10.1101/2022.06.28.22277016
A1 Breznik, Jessica A.
A1 Rahim, Ahmad
A1 Kajaks, Tara
A1 Hagerman, Megan
A1 Bilaver, Lucas
A1 Colwill, Karen
A1 Dayam, Roaya M.
A1 Gingras, Anne-Claude
A1 Verschoor, Chris P.
A1 McElhaney, Janet E.
A1 Bramson, Jonathan L.
A1 Bowdish, Dawn M. E.
A1 Costa, Andrew P.
YR 2022
UL http://medrxiv.org/content/early/2022/06/29/2022.06.28.22277016.abstract
AB Objectives To identify factors that contribute to protection from infection with the Omicron variant of SARS-CoV-2 in older adults in nursing and retirement homes.Design Longitudinal cohort study with retrospective analysis of infection risk.Setting and Participants 997 residents of nursing and retirement homes from Ontario, Canada, in the COVID-in-LTC study.Methods Residents with three mRNA dose vaccinations were included in the study. SARS-CoV-2 infection was determined by positive nasopharyngeal PCR test and/or circulating anti-nucleocapsid IgG antibodies. Cumulative probability of Omicron infection after recent COVID-19 was assessed by log-rank test of Kaplan-Meier curves. Cox regression was used to assess risk of Omicron infection by age, sex, mRNA vaccine combination, whether individuals received a fourth dose, as well as recent COVID-19.Results 171 residents (17.2%) had a presumed Omicron variant SARS-CoV-2 infection between December 15, 2021 (local start of the first Omicron wave) and May 3, 2022. Risk of Omicron infection was not different by age [hazard ratio (95% confidence interval): 1.01 (0.99-1.02)], or in women compared to men [0.97 (0.70-1.34)], but infection risk decreased 47% with three vaccine doses of mRNA-1273 (Moderna) compared to BNT162b2 (Pfizer) [0.53 (0.31-0.90)], 81% with any fourth mRNA vaccine dose [0.19 (0.12-0.30)], and 48% with SARS-CoV-2 infection in the 3 months prior to beginning of the Omicron wave [0.52, (0.27-0.99)].Conclusions and Implications Vaccine type (i.e., mRNA-1273/Spikevax vs BNT162b2/Cominarty), any fourth vaccine dose, and hybrid immunity from recent COVID-19, were protective against infection with the Omicron variant. These data emphasize the importance of vaccine type, and number of vaccine doses, in maintenance of protective immunity and reduction of risk of Omicron variant breakthrough infection. These findings promote continued public health efforts to support vaccination programs and monitor vaccine immunogenicity in older adults.Brief summary Risk of infection with the SARS-CoV-2 Omicron variant in older adults in early 2022 was reduced with triple mRNA-1273 vaccination, any fourth dose vaccine, and within three months of prior COVID-19.Competing Interest StatementACG has received research funds from a research contract with Providence Therapeutics Holdings, Inc for other projects. The authors have no financial relationship with any organization that may have an interest and have no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was funded by a grant from Canadian COVID-19 Immunity Task Force and Public Health Agency of Canada awarded to Costa and Bowdish. Gingras is the Canada Research Chair in Functional Proteomics and is a member of CoVaRR-Net, the CIHR Coronavirus Variants Rapid Response Network. Bowdish is the Canada Research Chair in Aging & Immunity. Costa is the Schlegel Chair in Clinical Epidemiology and Aging.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Hamilton Integrated Research Ethics Board of McMaster University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.